Duloxetine in the management of diabetic peripheral neuropathic pain.

Patient Prefer Adherence · 2011 · PMC3150163 · PMID 21845034

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The primary study endpoint of reduction in mean weekly 24-hour average pain score from baseline was reached in duloxetine 60 and 120 mg/day groups, but efficacy of 20 mg/day compared with placebo did not reach statistical significance and 120 mg/day was not significantly better than 60 mg/day.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.